147 related articles for article (PubMed ID: 32730518)
21. Response, survival, and toxicity after iodine-131-metaiodobenzylguanidine therapy for neuroblastoma in preadolescents, adolescents, and adults.
Polishchuk AL; Dubois SG; Haas-Kogan D; Hawkins R; Matthay KK
Cancer; 2011 Sep; 117(18):4286-93. PubMed ID: 21387264
[TBL] [Abstract][Full Text] [Related]
22. [131I]MIBG as a first line treatment in advanced neuroblastoma.
Hoefnagel CA; De Kraker J; Valdés Olmos RA; Voûte PA
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):61-4. PubMed ID: 9002752
[TBL] [Abstract][Full Text] [Related]
23. Toxicity of upfront ¹³¹I-metaiodobenzylguanidine (¹³¹I-MIBG) therapy in newly diagnosed neuroblastoma patients: a retrospective analysis.
Bleeker G; Schoot RA; Caron HN; de Kraker J; Hoefnagel CA; van Eck BL; Tytgat GA
Eur J Nucl Med Mol Imaging; 2013 Oct; 40(11):1711-7. PubMed ID: 23921531
[TBL] [Abstract][Full Text] [Related]
24. Arsenic Trioxide as a Radiation Sensitizer for 131I-Metaiodobenzylguanidine Therapy: Results of a Phase II Study.
Modak S; Zanzonico P; Carrasquillo JA; Kushner BH; Kramer K; Cheung NK; Larson SM; Pandit-Taskar N
J Nucl Med; 2016 Feb; 57(2):231-7. PubMed ID: 26742708
[TBL] [Abstract][Full Text] [Related]
25. Primary hypothyroidism and 131I-MIBG therapy in neuroblastoma.
Picco P; Garaventa A; Claudiani F; Garibaldi L; Borrone C
Lancet; 1993 Jul; 342(8862):57. PubMed ID: 8100332
[No Abstract] [Full Text] [Related]
26. Radiolabeled metaiodobenzylguanidine for the treatment of neuroblastoma.
DuBois SG; Matthay KK
Nucl Med Biol; 2008 Aug; 35 Suppl 1(Suppl 1):S35-48. PubMed ID: 18707633
[TBL] [Abstract][Full Text] [Related]
27. The role of 131I-metaiodobenzylguanidine (MIBG) therapy in unresectable and compromising localised neuroblastoma.
Schoot RA; Bleeker G; Caron HN; van Eck BL; Heij HA; de Kraker J; Tytgat GA
Eur J Nucl Med Mol Imaging; 2013 Oct; 40(10):1516-22. PubMed ID: 23740371
[TBL] [Abstract][Full Text] [Related]
28. [Radio iodized metaiodobenzylguanidine (MIBG) in the treatment of neuroblastoma: modalities and indications].
Défachelles AS; Cougnenc O; Carpentier P
Bull Cancer; 2011 May; 98(5):559-69. PubMed ID: 21609890
[TBL] [Abstract][Full Text] [Related]
29. Role of 131I-metaiodobenzylguanidine (MIBG) in the treatment of neuroendocrine tumours. Experience of the National Cancer Institute of Milan.
Castellani MR; Chiti A; Seregni E; Bombardieri E
Q J Nucl Med; 2000 Mar; 44(1):77-87. PubMed ID: 10932604
[TBL] [Abstract][Full Text] [Related]
30. Incidence of subclinical and overt hypothyroidism in children treated with [131I]mIBG: a systematic review and meta-analysis.
Fiz F; Piticchio T; Bottoni G; Sorrentino S; Fragola M; Livellara V; Trimboli P; Piccardo A
Q J Nucl Med Mol Imaging; 2024 Mar; 68(1):40-47. PubMed ID: 38319674
[TBL] [Abstract][Full Text] [Related]
31. 131I-MIBG followed by consolidation with busulfan, melphalan and autologous stem cell transplantation for refractory neuroblastoma.
French S; DuBois SG; Horn B; Granger M; Hawkins R; Pass A; Plummer E; Matthay K
Pediatr Blood Cancer; 2013 May; 60(5):879-84. PubMed ID: 23024113
[TBL] [Abstract][Full Text] [Related]
32. [(131)I] and [(125)I] metaiodobenzylguanidine therapy in macroscopic and microscopic tumors: a comparative study in SK-N-SH human neuroblastoma and PC12 rat pheochromocytoma xenografts.
Rutgers M; Buitenhuis CK; van der Valk MA; Hoefnagel CA; Voûte PA; Smets LA
Int J Cancer; 2000 Dec; 90(6):312-25. PubMed ID: 11180134
[TBL] [Abstract][Full Text] [Related]
33. Estimated Internal and External Radiation Exposure of Caregivers of Patients With Pediatric Neuroblastoma Undergoing 131I Metaiodobenzylguanidine Therapy: A Prospective Pilot Study.
Han S; Yoo SH; Koh KN; Lee JJ
Clin Nucl Med; 2017 Apr; 42(4):271-274. PubMed ID: 28098666
[TBL] [Abstract][Full Text] [Related]
34. Minimizing nuclear medicine technologist radiation exposure during 131I-MIBG therapy.
Turpin BK; Morris VR; Lemen L; Weiss BD; Gelfand MJ
Health Phys; 2013 Feb; 104(2 Suppl 1):S43-6. PubMed ID: 23287519
[TBL] [Abstract][Full Text] [Related]
35. Treatment with meta-[131I]iodobenzylguanidine and cisplatin in stage IV neuroblastoma.
Mastrangelo S; Tornesello A; Diociaiuti L; Riccardi R; Rufini V; Troncone L
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):69-71. PubMed ID: 9002754
[TBL] [Abstract][Full Text] [Related]
36. Feasibility and effectiveness of treatment strategy of tandem high-dose chemotherapy and autologous stem cell transplantation in combination with
Suh JK; Koh KN; Min SY; Kim YS; Kim H; Im HJ; Namgoong JM; Kim DY; Ahn SD; Lee JJ; Seo JJ
Pediatr Transplant; 2020 Mar; 24(2):e13658. PubMed ID: 31960542
[TBL] [Abstract][Full Text] [Related]
37. Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma.
DuBois SG; Messina J; Maris JM; Huberty J; Glidden DV; Veatch J; Charron M; Hawkins R; Matthay KK
J Clin Oncol; 2004 Jun; 22(12):2452-60. PubMed ID: 15197208
[TBL] [Abstract][Full Text] [Related]
38. Thyroidal uptake and radiation dose after repetitive I-131-MIBG treatments: influence of potassium iodide for thyroid blocking.
Brans B; Monsieurs M; Laureys G; Kaufman JM; Thierens H; Dierckx RA
Med Pediatr Oncol; 2002 Jan; 38(1):41-6. PubMed ID: 11835235
[TBL] [Abstract][Full Text] [Related]
39. Secondary myelodysplastic syndrome and leukemia following 131I-metaiodobenzylguanidine therapy for relapsed neuroblastoma.
Weiss B; Vora A; Huberty J; Hawkins RA; Matthay KK
J Pediatr Hematol Oncol; 2003 Jul; 25(7):543-7. PubMed ID: 12847321
[TBL] [Abstract][Full Text] [Related]
40. Patient dosimetry after 131I-MIBG therapy for neuroblastoma and carcinoid tumours.
Monsieurs MA; Thierens HM; Vral A; Brans B; De Ridder L; Dierckx RA
Nucl Med Commun; 2001 Apr; 22(4):367-74. PubMed ID: 11338046
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]